Fig. 5

Potential mechanisms resistant to first-generation EGFR inhibitors and survival benefits of osimeritinib for patients developing T790M mutation. Resistance reasons to first-generation EGFR TKIs were described in the cohorts of EGFR 19delins (A) and EGFR 19del (B). C Kaplan-Meier curves comparing the PFS between patients with EGFR 19delins and those with EGFR 19del after administration of osimeritinib as second-line therapy when developing EGFR T790M resistance